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Abstract
Recent genome-wide association studies of glioma have led to the discovery of single nucleotide polymorphisms (SNPs) 
at 25 loci influencing risk. Gliomas are heterogeneous, hence to investigate the relationship between risk SNPs and glioma 
subtype we analysed 1659 tumours profiled for IDH mutation, TERT promoter mutation and 1p/19q co-deletion. These data 
allowed definition of five molecular subgroups of glioma: triple-positive (IDH mutated, 1p/19q co-deletion, TERT promoter 
mutated); TERT-IDH (IDH mutated, TERT promoter mutated, 1p/19q-wild-type); IDH-only (IDH mutated, 1p/19q wild-
type, TERT promoter wild-type); triple-negative (IDH wild-type, 1p/19q wild-type, TERT promoter wild-type) and TERT-
only (TERT promoter mutated, IDH wild-type, 1p/19q wild-type). Most glioma risk loci showed subtype specificity: (1) the 
8q24.21 SNP for triple-positive glioma; (2) 5p15.33, 9p21.3, 17p13.1 and 20q13.33 SNPs for TERT-only glioma; (3) 1q44, 
2q33.3, 3p14.1, 11q21, 11q23.3, 14q12, and 15q24.2 SNPs for IDH mutated glioma. To link risk SNPs to target candidate 
genes we analysed Hi-C and gene expression data, highlighting the potential role of IDH1 at 2q33.3, MYC at 8q24.21 and 
STMN3 at 20q13.33. Our observations provide further insight into the nature of susceptibility to glioma.
Introduction
Diffuse gliomas are the most common malignant primary 
brain tumour affecting adults with around 26,000 newly 
diagnosed cases each year in Europe [9]. Diffuse gliomas 
have traditionally been classified into oligodendroglial and 
astrocytic tumours and are graded II–IV, with the most com-
mon form—Glioblastoma (GBM) or glioma grade IV—typi-
cally having a median survival of only 15 months [2].
Despite glioma being an especially devastating malig-
nancy little is known about its aetiology and aside from 
exposure to ionising radiation that accounts for very few 
cases no environmental or lifestyle factor has been unambig-
uously linked to risk [2]. Recent genome-wide association 
studies (GWAS) have, however, enlightened our understand-
ing of glioma genetics identifying single-nucleotide poly-
morphisms (SNPs) at multiple independent loci influencing 
risk [22, 25, 35, 44, 49, 51, 63]. While understanding the 
functional basis of these risk loci offers the prospect of gain-
ing insight into the development of glioma, few have been 
deciphered. Notable exceptions are the 17p13.1 locus, where 
the risk SNP rs78378222 disrupts TP53 polyadenylation 
[51] and the 5p15.33 locus, where the risk SNP rs10069690 
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creates a splice-donor site leading to an alternate TERT 
splice isoform lacking telomerase activity [24].
Since the aetiological basis of glioma subtypes is likely 
to reflect different developmental pathways it is not per-
haps surprising that subtype-specific associations have 
been shown for GBM (5p15.33, 7p11.2, 9p21.3, 11q14.1, 
16p13.33, 16q12.1, 20q13.33 and 22q13.1) and for non-
GBM glioma (1q44, 2q33.3, 3p14.1, 8q24.21, 10q25.2, 
11q21, 11q23.2, 11q23.3, 12q21.2, 14q12 and 15q24.2) [35]. 
Recent large-scale sequencing projects have identified IDH 
mutation, TERT promoter mutation and 1p/19q co-deletion 
as cancer drivers in glioma. These findings have improved 
the subtyping of glioma [5, 12, 26, 27] and this information 
has been incorporated into the revised 2016 WHO classifica-
tion of glial tumours [32]. Since these mutations are early 
events in glioma development, any relationship between 
risk SNP and molecular profile should provide insight into 
glial oncogenesis. Evidence for the existence of such sub-
type specificity is already provided by the association of the 
8q24.21 (rs55705857) risk variant with 1p/19q co-deletion, 
IDH mutated glioma [13]. Additionally, it has been proposed 
that associations may exist between risk SNPs at 5p15.33, 
9p21.3 and 20q13.33 and IDH wild-type glioma [10], as 
well as 17p13.1 and TERT promoter, IDH mutated glioma 
without 1p/19q co-deletion [12].
To gain a more comprehensive understanding of the rela-
tionship between the 25 glioma risk loci and tumour subtype 
we analysed three patient series totalling 2648 cases. Since 
generically the functional basis of GWAS cancer risk loci 
appear primarily to be through regulatory effects [53], we 
analysed Hi-C and gene expression data to gain insight into 
the likely target gene/s of glioma risk SNPs.
Materials and methods
Data sources
We analysed data from three non-overlapping case series: 
TCGA, French GWAS, French sequencing. Details of these 
datasets are provided below and are summarised in Table 1.
TCGA 
Raw genotyping files (.CEL) for the Affymetrix Genome-
wide version 6 array were downloaded for germline (i.e. 
normal blood) glioma samples from The Cancer Genome 
Atlas (TCGA, dbGaP study accession: phs000178.v1.p1). 
Controls were from publicly accessible genotype data gen-
erated by the Wellcome Trust Case–Control Consortium 2 
(WTCCC2) analysis of 2699 individuals from the 1958 Brit-
ish birth cohort (1958-BC) [41]. Genotypes were generated 
using the Affymetrix Power Tools Release 1.20.5 using the Ta
bl
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Birdseed (v2) calling algorithm (https ://www.affym etrix 
.com/suppo rt/devel oper/power tools /chang elog/index .html) 
and PennCNV [59]. After quality control (Supplementary 
Figs. 1, 2, Supplementary Table 1) there were 521 TCGA 
glioma cases and 2648 controls (Table 1). Glioma tumour 
molecular data (IDH mutation, 1p/19q co-deletion, TERT 
promoter mutation) were obtained from Ceccarelli et al. 
[6]. Further data (EGFR amplification/activating mutations, 
CDKN2A deletion) were obtained from the cBioportal for 
cancer genomics [15]. After adjustment for principal com-
ponents there was minimal evidence of over-dispersion infla-
tion (λ = 1.01; Supplementary Fig. 2).
French GWAS
The French-GWAS [25, 44] comprised 1423 patients with 
newly diagnosed grade II–IV diffuse glioma attending the 
Service de Neurologie Mazarin, Groupe Hospitalier Pitié-
Salpêtrière Paris. The controls (n = 1190) were ascertained 
from the SU.VI.MAX (SUpplementation en VItamines et 
MinerauxAntioXydants) study of 12,735 healthy subjects 
(women aged 35–60 years; men aged 45–60 years) [19]. 
Tumours from patients were snap-frozen in liquid nitrogen 
and DNA was extracted using the QIAmp DNA minikit, 
according to the manufacturer’s instructions (Qiagen, Venlo, 
LN, USA). DNA was analysed for large-scale copy num-
ber variation by comparative genomic hybridisation (CGH) 
array as previously described [16, 21]. For tumours not ana-
lysed by CGH array, 1p/19q co-deletion status was assigned 
using PCR microsatellites, and EGFR-amplification and 
CDKN2A-p16-INK4a homozygous deletion by quantitative 
PCR. IDH1, IDH2 and TERT promoter mutation status was 
assigned by sequencing [26, 45].
French sequencing
Eight hundred and fifteen patients newly diagnosed grade 
II–IV diffuse glioma were ascertained through the Service 
de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière 
Paris. Genotypes for the 25 risk SNPs were obtained by 
universal-tailed amplicon sequencing in conjunction with 
Miseq technology (Illumina Inc.). Genotypes were called 
using GATK (Genome Analysis ToolKit, version 3.6-0-
g89b7209) software. Duplicated samples and individuals 
with low call rate (< 90%) were excluded (n = 111). Molec-
ular profiling of tumour samples was carried out as per the 
French GWAS.
Unrelated French controls were obtained from the 3C 
Study (Group 2003) [17] a population-based, prospec-
tive study of the relationship between vascular factors and 
dementia being carried out in Bordeaux, Montpellier, and 
Dijon. Genotyping of controls was performed using Illumina 
Human 610-Quad BeadChips. To recover untyped genotypes 
imputation using IMPUTE2 software was performed using 
1000 genomes multi-ethnic data (1000 G phase 1 integrated 
variant set release v3) as reference. SNPs genotypes were 
retained call rates were > 98%, Hardy–Weinberg equilib-
rium (HWE) P value > 1 × 10−6, minor allele frequency 
(MAF) > 1%. After quality control, 704 cases and 5527 con-
trols were available for analysis (Table 1).
Statistical analysis
Test of association between SNP and glioma molecular 
subgroup was performed using SNPTESTv2.5 [33] under 
an additive frequentist model. Where appropriate, principal 
components, generated using common SNPs, were included 
in the analysis to limit the effects of cryptic population strati-
fication that otherwise might cause inflation of test statistics. 
Eigenvectors for the TCGA study were inferred using smart-
pca (part of EIGENSOFTv2.4) [40] by merging cases and 
controls with phase II HapMap samples [25].
To ensure reliability when restricting cases to per-group 
low sample counts, imputed genotypes were thresholded at a 
probability > 0.9 (e.g. –method threshold in SNPtest) for the 
TCGA and French-GWAS studies. For the French-sequence 
study we used –method expected, as we were comparing 
genotypes from directly sequenced cases against imputed 
controls. We compared control frequencies to those from 
European 1000 genomes project to ensure the validity of 
this approach.
Meta-analyses were performed using the fixed-effects 
inverse-variance method based on the β estimates and stand-
ard errors from each study using META v1.6 [30]. Cochran’s 
Q statistic was used to test for heterogeneity [20].
Risk allele number and age at diagnosis
For imputed SNPs a genotype probability threshold > 0.9 
was used. The age and survival distribution of cases carrying 
additive combinations of risk alleles were assessed for the 
25 SNPs across the molecular subgroups. Trend lines were 
estimated using linear regression in R and plotted using the 
ggplot2 package [62]. Association between risk allele num-
ber and age was assessed using Pearson correlation.
Survival analysis
Survival plots were generated using the survfit package in 
R which computes an estimate of a survival curve for cen-
sored data using the Kaplan–Meier method. Log-rank tests 
were used to compare curves between groups and power 
to demonstrate a relationship between different groups and 
overall survival was estimated using sample size formulae 
for comparative binomial trials. The Cox proportional-haz-
ards regression model was used to investigate the association 
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between survival and age, grade, molecular group and num-
ber of risk alleles. Individuals were excluded if they died 
within a month of surgery. Date of surgery was used as a 
proxy for the date of diagnosis.
Expression quantitative trait locus analysis
We searched for expression quantitative trait loci (eQTLs) 
in 10 brain regions using the V6p GTEx [31] portal (https 
://gtexp ortal .org/home/) as well as in whole blood using the 
blood eQTL browser [61] (https ://molge nis58 .targe t.rug.nl/
blood eqtlb rowse r/).
Hi‑C analysis
We examined for significant contacts between glioma 
risk SNPs and nearby genes using the HUGIn browser 
[34], which is based on analysis by Schmitt et al. [48]. We 
restricted the analysis to Hi-C data generated on H1 Embry-
onic Stem Cell and Neuronal Progenitor cell lines, as origi-
nally described in Dixon et al. [11]. Plotted topologically 
associating domain (TAD) boundaries were obtained from 
the insulating score method [8] at 40-kb bin resolution. We 
searched for significant interactions between bins overlap-
ping the glioma risk SNP and all other bins within 1 Mb at 
each locus (i.e. “virtual 4C”).
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was carried out using 
version 3.0 with gene sets from Molecular Signatures Data-
base (MSigDB) v6.0 [36, 52], restricted to the C2 canonical 
pathways sets (n = 1329). Analysis was carried out using 
default settings, with the exception of removing restrictions 
on gene set size. RSEM normalised mRNASeq expression 
data for 20,501 genes in 676 glioma cases from TCGA were 
downloaded from the Broad Institute TCGA GDAC (http://
gdac.broad insti tute.org/). These were assigned molecular 
groupings using sample information from Supplementary 
Table 1 of Ceccarelli et al. [6].
Results
Descriptive characteristics of datasets
We studied three non-overlapping glioma case–control series 
of Northern European ancestry totalling 2648 cases and 
9365 controls (Table 1). For 1659 of the 2648 cases infor-
mation on tumour, 1p/19q co-deletion, TERT promoter and 
IDH mutation status was available (Fig. 1). Using these data 
allowed definition of five molecular subgroups of glioma: 
triple-positive (IDH mutated, 1p/19q co-deletion, TERT 
promoter mutated); TERT-IDH (IDH mutated, TERT pro-
moter mutated, 1p/19q-wild-type); IDH-only (IDH mutated, 
1p/19q wild-type, TERT promoter wild-type); TERT-only 
(TERT promoter mutated, IDH wild-type, 1p/19q wild-type) 
and triple-negative (IDH wild-type, 1p/19q wild-type, TERT 
promoter wild-type). As only 29 cases were classified as 
IDH mutation, 1p/19q co-deletion and TERT promoter wild-
type, we restricted subsequent analyses to the five groups as 
above. Table 1 also shows grouping of the 1960 cases adopt-
ing the WHO 2016 classification of glial tumours into five 
categories (Astrocytoma with IDH mutation, IDH wild-type 
Fig. 1  Molecular classification of diffuse glioma and frequency of each subgroup in the TCGA, French-GWAS and French sequencing case 
series
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astrocytoma, Oligodendroglioma with 1p/19q co-deletion, 
GBM with IDH mutation and IDH wild-type GBM) (Sup-
plementary Table 2 [Online Resource 1]).
SNP selection
We analysed 25 SNPs, which had been reported to show the 
strongest genome-wide significant association with glioma 
in our recent meta-analysis of 12,496 cases and 18,190 con-
trols [35] (Table 2). In the current analysis all of the SNPs 
exhibited a consistent direction of effect with that previously 
reported, albeit some weakly [Supplementary Fig. 4 (Online 
Resource 1), Supplementary Table 3 (Online Resource 2)].
Relationship between risk SNP and molecular 
subgroup
In the first instance, we examined whether the associa-
tions at the 25 risk loci were broadly defined by IDH sta-
tus. We observed significant association for IDH mutated 
group with 1q44 (rs12076373), 2q33.3 (rs7572263), 3p14.1 
(rs11706832), 8q24.21 (rs55705857), 11q21 (rs7107785), 
11q23.3 (rs12803321), 14q12 (rs10131032), 15q24.2 
(rs77633900) and 17p13.1 (rs78378222) risk SNPs. In addi-
tion, we found strong associations with IDH wild-type glio-
mas at 5p15.33 (rs10069690), 7p11.2 (rs75061358), 9p21.3 
(rs634537), and 20q13.33 (rs2297440) (Supplementary 
Fig. 5 [Online Resource 1], Supplementary Table 3 [Online 
Resource 2]). Of particular note was the finding that many 
of the risk loci recently discovered which were reported to 
be associated with non-GBM (1q44, 2q33.3, 3p14.1, 11q21, 
14q12, 15q24.2) [35] showed a strong association with IDH 
mutant glioma.
Following on from this we performed a more detailed 
stratified analysis based on classifying the glioma tumours 
into the five molecularly defined groups. We found a 
strong association with IDH mutated tumours at 8q24.21 
(rs55705857), in particular with triple-positive glioma 
[P = 1.27 × 10−37, OR = 9.30 (6.61–13.08)], which cor-
responds to the WHO 2016 oligodendroglioma classifica-
tion [Supplementary Fig. 6 (Online Resource 1), Supple-
mentary Table 3 (Online Resource 2)]. Furthermore, we 
confirmed the previously reported associations at 5p15.33 
(rs10069690), 9p21.3 (rs634537), 17p13.1 (rs78378222) 
and 20q13.33 (rs2297440) with TERT-only glioma in each 
of the three series [12]. Finally, we found suggestive evi-
dence for an association between 22q13.1 (rs2235573) with 
TERT-only glioma, as well as 11q21 (rs7107785), 11q23.2 
(rs648044), and 12q21.2 (rs1275600) with triple-positive 
glioma [Fig. 2, Supplementary Table 3 (Online Resource 2)].
In addition to data on 1p/19q co-deletion, TERT promoter 
and IDH mutation, for 1955 of the tumours we had informa-
tion on EGFR amplification and CDKN2A deletion status 
(Table 1). Using these data we examined for an association 
with EGFR amplification and CDKN2A deletion, particu-
larly focusing on the 7p11.2 (rs75061358 and rs11979158) 
and 9p21.3 (rs634537) risk SNPs in view of the fact that 
these loci map in or near EGFR and CDKN2A, respectively 
(Supplementary Figs. 7, 8 [Online Resource 1], Supplemen-
tary Table 3 [Online Resource 2]). At 7p11.2, the intergenic 
Table 2  Overview of glioma risk SNPs at the 25 loci
The risk allele frequency (RAF) is from European samples from 1000 
genomes project. At 10q25.2, rs11599775 [35] failed sequencing so 
the originally reported SNP rs11196067 [25] was used
The risk allele is emboldened and the minor allele underlined
Locus SNP Alleles RAF Reported subtype
1p31.3 [35] rs12752552 
[35]
T/C 0.87 GBM
1q32.1 [35] rs4252707 [35] G/A 0.22 Non-GBM
1q44 [35] rs12076373 
[35]
G/C 0.84 Non-GBM
2q33.3 [35] rs7572263 [35] A/G 0.76 Non-GBM
3p14.1 [35] rs11706832 
[35]
A/C 0.46 Non-GBM
5p15.33 [49] rs10069690 
[35]
C/T 0.28 GBM
7p11.2 [44] rs75061358 
[35]
T/G 0.10 GBM
7p11.2 [44] rs11979158 
[44]
A/G 0.83 GBM
8q24.21 [49] rs55705857 [13, 
22]
A/G 0.06 Non-GBM
9p21.3 [49, 63] rs634537 [35] T/G 0.41 GBM
10q24.33 [35] rs11598018 
[35]
C/A 0.46 Non-GBM
10q25.2 [25] rs11196067 
[25]
A/T 0.58 Non-GBM
11q14.1 [35] rs11233250 
[35]
C/T 0.87 GBM
11q21 [35] rs7107785 [35] T/C 0.48 Non-GBM
11q23.2 [25] rs648044 [25] A/G 0.39 Non-GBM
11q23.3 [49] rs12803321 
[35]
G/C 0.64 Non-GBM
12q21.2 [25] rs1275600 [35] T/A 0.60 Non-GBM
14q12 [35] rs10131032 
[35]
G/A 0.92 Non-GBM
15q24.2 [25] rs77633900 
[35]
G/C 0.09 Non-GBM
16p13.3 [35] rs2562152 [35] A/T 0.85 GBM
16p13.3 [35] rs3751667 [35] C/T 0.21 Non-GBM
16q12.1 [35] rs10852606 
[35]
T/C 0.71 GBM
17p13.1 [51] rs78378222 
[51]
T/G 0.01 All
20q13.33 [49, 
63]
rs2297440 [35] T/C 0.80 GBM
22q13.1 [35] rs2235573 [35] G/A 0.51 GBM
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variant rs75061358, which is located in the genomic vicin-
ity of EGFR, was associated with EGFR amplified tumours 
and not those without amplification. There was a less strong 
association with EGFR amplification seen with the second 
independent signal at the locus defined by rs11979158, 
which is intronic within EGFR itself. At 9p21.3 rs634537, 
which is intronic within CDKN2B-AS1 and in the vicin-
ity of CDKN2A and CDKN2B, was not associated with 
CDKN2A deletion status. Low grade gliomas tend to be 
EGFR wild-type and p16 wild-type tumours and, there-
fore, as anticipated many non-GBM risk SNPs were most 
strongly associated with these tumours; notably 2q33.3 
(rs7572263), 3p14.1 (rs11706832), 8q24.21 (rs55705857), 
10q25.2 (rs11196067), 11q23.3 (rs12803321) (Supplemen-
tary Figs. 7, 8 [Online Resource 1], Supplementary Table 3 
[Online Resource 2]).
Polygenic contribution to age at diagnosis 
and patient survival
Patient survival by molecular subgroup in each of the three 
series was consistent with previous published reports [5, 12]; 
specifically, patients with triple-positive tumours had the 
best prognosis whilst those with TERT-only tumours had 
the worst outcome (Supplementary Fig. 3 [Online Resource 
1]). We investigated whether an increased burden of glioma 
risk alleles might be associated with earlier age at diagnosis 
(i.e. indicative of influence on glioma initiation) or survival 
(indicative of influence on glioma progression). There was a 
slight albeit, non-significant trend towards decreased age at 
diagnosis with increased risk allele number in the IDH-only, 
TERT-only and triple-positive molecular subgroup, but with 
decreased risk allele number in the TERT-IDH and Triple-
negative tumours (Supplementary Fig. 9 [Online Resource 
1]). We found no overall relationship between age and risk 
allele number, or for the individual molecular groups (Sup-
plementary Table 4 [Online Resource 1]). Examining each 
SNP individually, only rs55705857 at 8q24.21 was nomi-
nally associated with age (Supplementary Table 4 [Online 
Resource 1]).
We used Cox Proportional-Hazards Regression to investi-
gate whether burden of glioma risk was associated with sur-
vival, with each risk allele coded as 0, 1 or 2. As expected, 
age, grade and all molecular group (Triple-negative, Triple-
positive, TERT-only, IDH-only and TERT-IDH) were strongly 
associated with decreased survival. Intriguingly, the number 
of risk alleles was associated with increased survival (Supple-
mentary Table 5 [Online Resource 1]; P < 10−4) with 1q32.1 
Fig. 2  Association between the 25 risk loci and glioma subgroup. Horizontal red line corresponds to an odds ratio of 1.0
Acta Neuropathologica 
1 3
(rs4252707), 11q23.3 (rs12803321) and 11q21 (rs7107785) 
each being nominally associated with survival, independent 
of age and molecular subgroup. Considering the relationship 
between burden of glioma risk alleles and survival in each 
molecular subgroup a consistent association with increased 
survival was shown in Triple-positive, Triple-negative and 
TERT-only molecular groups but not in IDH-only and TERT-
IDH groups.
Biological inference of risk loci
Since genomic spatial proximity and chromatin looping inter-
actions are fundamental for the regulation of gene expression 
[42], we interrogated physical interactions at respective risk 
loci in embryonic stem cells and neuronal progenitor cells 
using Hi-C data. We also sought to gain insight into the pos-
sible biological mechanisms for associations by performing 
expression quantitative trait locus (eQTL) analysis using 
mRNA expression data in 10 brain regions using the GTEx 
portal.
We identified significant Hi-C contacts from the genomic 
regions which encompass 14 of the 25 risk loci implicating a 
number of presumptive candidate genes. For two of these, can-
didacy was supported by eQTL data. (Table 3; Supplementary 
Fig. 10 [Online Resource 1]; Supplementary Table 6 [Online 
Resource 3]). Notably at 2q33.3, there was a significant loop-
ing interaction between the risk SNP and IDH1/IDH1-AS1, as 
well as with EGFR/EGFR-AS1 at 7p11.2, CDKN2A/CDKN2B 
at 9p21.3, NFASC at 1q32.1 and LRIG1 at 3p14.1. At the 
8q24.21 gene desert Hi-C data revealed a significant interac-
tion between the risk SNP rs55705857 and MYC, as well as 
lincRNAs in the region such as PCAT1/PCAT2. Additionally, 
the risk SNP rs12803321 at 11q23.3 was significantly associ-
ated with PHLDB1 expression in the brain.
Pathway analysis
To potentially gain further insight into the biological basis 
of subtype associations, we performed a gene-set enrich-
ment analysis (GSEA) analysing gene expression data from 
TCGA (Supplementary Table 7 [Online Resource 4]). While 
we did not identify any significantly altered gene sets (at 
FDR q value < 0.1), the most significantly expressed genes 
in subgroups was upregulation of PI3K signalling shown in 
1p/19q co-deleted tumours (Supplementary Table 7 [Online 
Resource 4]).
Discussion
Our findings provide further support for subtype-specific 
associations for glioma risk loci. Specifically, we confirm 
the strong relationship between the 8q24.21 (rs55705857) 
risk variant and Triple-positive glioma. Moreover, we sub-
stantiate the proposed specific associations between 5p15.33 
(rs10069690) and 20q13.33 (rs2297440) variants with TERT 
promoter mutations, 9p21.3 (rs634537) with TERT-only 
glioma, as well as 17p13.1 (rs78378222) with TERT-IDH 
glioma. Other loci such as 1q32.1 (rs4252707) and 10q25.2 
(rs11196067) appear to have more generic effects.
Although preliminary, and in part speculative, our analy-
sis delineates potential candidate disease mechanisms across 
the 25 glioma risk loci (Table 3; Fig. 3). First, maintenance 
of telomeres is central to cell immortalization [57], and is 
generally considered to require mutually exclusive muta-
tions in either the TERT promoter or ATRX. The risk alleles 
at 5p15.33 (TERT) and 10q24.33 (OBFC1) are associated 
with increased leukocyte telomere length, thereby support-
ing a relationship between SNP genotype and biology [56, 
57, 66]. While dysregulation of the telomere gene RTEL1 
has traditionally been assumed to represent the functional 
basis of the 20q13.33 locus, the glioma risk SNP does 
not map to the locus associated with telomere length [7, 
35]. Intriguingly, our analysis instead implicates STMN3 
at 20q13.33, whose over-expression promotes growth in 
GBM cells [68], suggesting an alternative mechanism by 
which the risk SNP influences glioma development. With 
respect to the 5p15.33 (TERT) and 10q24.33 (OBFC1) loci, 
it is unclear whether the effect on glioma risk is solely due 
to telomeres or is pleiotropic and involves multiple factors. 
For example, rs10069690 at 5p15.33 is strongly associated 
with TERT-only glioma, yet the TERT promoter mutation 
increases telomerase activity without necessarily affecting 
telomere length [6]. An intriguing hypothesis to test would, 
therefore, be to examine the impact of allele-specific effects 
of rs10069690 on telomere length in the context of gliomas 
carrying the TERT promoter mutation.
Second, the EGFR-AKT pathway involves EGFR at 
7p11.2, LRIG1 at 3p14.1, PHLDB1 at 11q23.3 and AKT3 at 
1q44. We showed a significant interaction between the risk 
SNP rs11979158 at 7p11.2 and EGFR, consistent with a cis-
regulatory effect on gene expression. Although the mecha-
nistic basis of the 7p11.2 locus has long been suspected to 
involve EGFR and is highly associated with classical GBM, 
emerging evidence suggests that additional components 
of the EGFR-AKT signalling pathway are implicated by 
non-GBM SNPs. At the IDH-only associated locus 3p14.1, 
LRIG1 is highly expressed in the brain and negatively regu-
lates the epidermal growth factor receptor (EGFR) signal-
ling pathway [18]. Reduced LRIG1 expression is linked to 
tumour aggressiveness, temozolomide resistance and radio-
resistance [60, 65]. Downstream components of EGFR-AKT 
signalling are implicated at 11q23.3 via PHLDB1, as well 
as 1p31.3 via JAK1 and 1q44 via AKT3. The risk allele 
of rs12803321 is associated with increased expression of 
PHLDB1, an insulin-responsive protein that enhances Akt 
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activation [70]. AKT3 at 1q44 is highly expressed in the 
brain and appears to respond to EGF in a PI3K dependent 
manner [38], with GBM cells containing amplified AKT3 
having enhanced DNA repair and resistance to radiation and 
temozolomide [54]. The risk allele of rs12752552 at 1p31.3 
is associated with increased JAK1 expression in brain tissue. 
Since JAK1 can be activated by EGF phosphorylation, it may 
be involved in astrocyte formation [3, 39, 50]. The 3p14.1 
and 11q23.3 loci are strongly associated with EGFR ampli-
fication negative gliomas, with a consistent albeit non-sig-
nificant trend at 1p31.3 and 1q44, consistent with elevated 
upstream EGFR activation masking their functional effects.
Third, the NAD pathway involves IDH1 at 2q33.3 and 
NNMT at 11q23.2. At 2q33.3 we detected a significant Hi-C 
interaction between the glioma risk SNP rs7572263 and 
IDH1/IDH1-AS1. Overexpression of IDH1 mutant proteins 
has been reported to sensitize glioma cells to radiation [29], 
providing an interesting mechanism to test the allele-specific 
effects of this SNP. IDH mutation causes de-regulation of 
NAD signalling [64]. Interestingly, therefore, at 11q23.2 
which is strongly associated with IDH mutated gliomas, 
the most convincing molecular mechanism is via NNMT, 
which encodes nicotinamide N-methyltransferase and is 
highly expressed in GBM relative to normal brain, causing 
methionine depletion-mediated DNA hypomethylation and 
accelerated tumour growth [23, 55].
Fourth, genes with established roles in neural develop-
ment may be involved. While the risk SNP rs4252707 at 
1q32.1 is within the intron of MDM4, the strongest evidence 
for a mechanistic effect was with NFASC. Neurofascin is 
involved in synapse formation during neural development 
[1] and, therefore, represents an attractive functional can-
didate for the association with glioma. Additionally at 
16p13.3 and 20q13.33, implicated genes SOX8 and STMN3 
are strongly expressed in the brain and thought to play a 
role in neural development [47, 68]. At 10q25.2, implicated 
gene TCF7L2 modifies beta-catenin signalling and controls 
oligodendrocyte differentiation [69]. Intriguingly, 10q25.2 
has previously been reported to be a risk locus for colorectal 
cancer [58], a tumour driven by wnt signalling, however, the 
risk SNP is not correlated with rs11196067 raising the pos-
sibility of tissue-specific regulation across the wider region.
Finally, the p53 pathway is involved at 17p13.1, where the 
risk SNP rs78378222 affects TP53 3′UTR poly-adenylation 
processing. In addition, the p53 target GLIPR1 [43] is impli-
cated at 12q21.2. Moreover, 12q21.2 is most strongly asso-
ciated with Triple-positive glioma, which does not feature 
TP53 mutation, consistent with wild-type p53 protein being 
required for the SNP to exert a functional effect.
As with many cancers, the exact point at which the risk 
SNPs exert their functional impact on glioma oncogenesis 
still remains to be elucidated, and we did not demonstrate a 
relationship between increased risk allele number and age Ta
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at diagnosis. Surprisingly we found a significant associa-
tion between increasing risk allele number and improved 
outcome. This result was consistent across the prognostic 
molecular groups, consistent with our observations not 
being due to an over-representation of the more favourable 
prognostic groups among patients with a higher burden of 
risk alleles. In addition, the distribution of risk allele num-
bers did not differ across the four groups (P = 0.3, ANOVA 
test). Examining the impact of an individual SNP’s impact 
on survival did not reveal any loci strongly associated with 
outcome. Collectively our findings suggest that, independent 
of other prognostic factors, the greater the number of risk 
alleles carried, the better the outcome.
In conclusion, we performed the most comprehensive 
association study between molecular subgroup and the 25 
recently identified glioma risk loci to date. While confirm-
ing previous observations, we show that the majority of risk 
loci are associated with IDH mutation. Through the integra-
tion of Hi-C and eQTL data, we have additionally sought to 
define candidate target genes underlying the associations. 
Collectively our observations highlight pathways critical to 
glioma susceptibility, notably neural development and NAD 
metabolism, as well as EGFR-AKT signalling. Intriguingly, 
we show here that the number of risk alleles is consistently 
associated with better outcome. Functional investigation in 
tumour and neural progenitor-based systems will be required 
to more fully elucidate these molecular mechanisms. Nota-
bly, IDH mutant tumours have been shown to reshape 3D 
chromatin organisation and may reveal new regulatory inter-
actions [14].
Our current analysis is based on defining glioma sub-
groups using only three primary markers. Given the extent 
of the missing heritability for glioma further expansion of 
GWAS by international consortia [35] is likely to result in 
the identification of additional risk variants. Additional 
molecular sub-grouping glioma resulting from ongoing 
large-scale tumour sequencing projects is likely to provide 
for further insights into glial oncogenesis and ultimately may 
suggest targets for novel therapeutic strategies.
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